drugset / Trial / NCT03905343
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
Phase 3
Terminated
25 enrolled
Swiss Cancer Institute
The Belgian Society of Medical Oncology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this trial is to assess if patients treated with the combination of ribociclib and endocrine therapy respond to treatment as fast as patients treated with chemotherapy only, without decreasing their quality of life (QoL).
Timeline
- Start
- 2019-06-25
- Primary completion
- 2021-04-15
- Completion
- 2021-04-15
Outcome
Outcome not reported
Stopped (Enrollment): “Feasibility (low patient accrual and financial reasons)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribociclib | Small molecule | 600 mg | Oral |